Looking for Cancer Genetic Testing?

Our advanced helps you understand your specific cancer in detail, empowering you and your medical team to make clearer, more informed treatment decisions.

What is tumour genomic testing?

What many people call “cancer genetic testing” is clinically known as .

Rather than looking at the DNA you inherited from your parents, our Insight tests analyse the DNA directly from your cancer cells. This helps your medical team better understand how your specific tumour behaves and what drives it.

RareCan Insight provides blood-based (also known as or testing).

Please note: these are not .

Choose the tumour genomic test that fits your needs

Add Your Heading Text Here

RareCan offers three blood-based . We provide comprehensive and targeted options for any type, alongside a specialised precision test for colorectal cancer.

All our tests are designed to give you and your clinical team clear, usable insight into your , helping you explore UK-relevant treatment and options.

What our solid tumour liquid biopsy tests cover:

Both of our tests analyse the that are most critical across a wide range of cancers, including:

TP53, BRCA1/2, KRAS, EGFR, BRAF, HER2, ALK, PIK3CA, , and NTRK.

The main difference between the two tests is the breadth of coverage and the number of additional included.

Our dedicated colorectal cancer test:

This test is specifically designed to analyse the and of colorectal tumours that have a . It also covers the essential used to aid in treatment decisions.

Our Dedicated Colorectal Cancer Test:

Explore our Insight liquid biopsy options

Insight CSB - Comprehensive Genomic Profiling of Solid Tumours from Blood

What it is:
The CSB test analyses a broad range of cancer-related genes from a blood sample to provide a detailed understanding of your – with results written for people, not just specialists.

What it is for:
Designed for people who want the fullest possible insight, particularly when:

Standard treatment options have been exhausted
You want to explore what else might exist beyond routine care
You want a report you can actually use in conversations about next steps

Why it is different:

Broader gene coverage than other leading market tests
UK-focused clinical trial matching, explained in context
A clear, human-readable summary – not just technical findings

Genes included:
The CSB panel analyses 523 genes for /, 59 genes for , and 23 genes for , covering the most frequently referenced and clinically relevant in rarer , including TP53, BRCA1/2, KRAS, EGFR, BRAF, HER2, ALK, PIK3CA, , NTRK and more.

Additional biomarkers:

Microsatellite instability (MSI), a feature of how DNA repair works
Tumour mutational burden (TMB), a measure of how many mutations are present
Tumour fraction (TFx), an estimate of the proportion of the cell-free DNA arising from the tumour

Price: £3,250

Get more information about the Insight CSB test

Book a free call to find out whether the Insight CSB is right for you

Ready to book an Insight CSB test? Click here to order a test today

Insight PCB - Precision Genomic Profiling of Colorectal Cancer from Blood

What it is:
The Insight PCB test focuses on the critical and , offering comprehensive coverage of , alongside essential , , and . This is done from a blood sample to provide a detailed understanding of your – with results written for people, not just specialists.

What it is for:
The test is designed to support , including the selection of:

Anti-EGFR Therapies (e.g. Panitumumab, Cetuximab)
BRAF Inhibitor Combinations (e.g. Encorafenib + Cetuximab)
Immune Checkpoint Inhibitors (e.g. Pembrolizumab, Nivolumab)
Targeted Therapies (e.g. HER2, TRK, MET inhibitors)

Why it is different:

Specifically designed to cover the most important genes and biomarkers for colorectal cancer patients
UK-focused clinical trial matching, explained in context
A clear, human-readable summary – not just technical findings

Genes included:
AKT, ALK, APC, BRAF, EGFR, ERBB2, FBXW7, FGFR2, FGFR3, HRAS, KRAS, MAP2K1, MAP2K2, MAPK1, MET, MLH1, MSH2, MSH6, NRAS, NTRK1, NTRK2, PIK3CA, PMS2, POLD1, POLE, PTEN, RET, ROS1, SMAD4, TP53, VEGF-A.

Additional biomarkers:

Microsatellite instability (MSI), a feature of how DNA repair works
Tumour mutational burden (TMB), a measure of how many mutations are present
Tumour fraction (TFx), an estimate of the proportion of the cell-free DNA arising from the tumour

Price: £2,500

Get more information about the Insight PCB test

Book a free call to find out whether the Insight PCB is right for you

Ready to book an Insight PCB test? Click here to order a test today

Insight TSB - Targeted Genomic Profiling of Solid Tumours from Blood

What it is:
The TSB test analyses a targeted set of cancer-related genes from a blood sample, providing clear insight into tumour changes over time, with the same emphasis on clarity and UK trial context.

What it is for:
Designed for people who:

Wish to track disease progression or molecular changes over time, or
Want more affordable access to key tumour genomics to explore what else might exist beyond routine care

Why it is different:

Broader coverage and better sensitivity than comparable tests
UK-focused clinical trial matching, explained in context
A clear, human-readable summary – not just technical findings

Genes included:
The TSB test detects 118 cancer-related genes, covering the most frequently referenced and clinically relevant in rarer , including TP53, BRCA1/2, KRAS, EGFR, BRAF, HER2, ALK, PIK3CA, , NTRK and more.

Additional biomarker:

Tumour fraction (TFx), an estimate of the proportion of the cell-free DNA arising from the tumour

Price: £2,200

Get more information about the Insight TSB test

Book a free call to find out whether the Insight TSB right for you

Ready to book an Insight TSB test? Click here to order a test today

Compare at a glance

Feature	InsightCSB	InsightTSB	InsightPCB
Cancer types:	All solid tumours	All solid tumours	Colorectal cancers
SNVs & InDels:	523 genes	118 genes	31 genes
CNVs	59 genes	N/a	12 genes
Fusions	23 genes	15 genes	9 genes
HLA genes	3	N/a	N/a
Histone genes	16	N/a	N/a
Tumour Mutation Burden (TMB)	Yes	N/a	Yes
Microsatellite Instability (MSI)	Yes	N/a	Yes
Tumour fraction (TFx)	Yes	Yes	Yes
Turnaround Time	28 days	20 days	28 days
Price	£3,250	£2,200	£2,500

Want to find out more?

Arrange a time to speak to one of our team

Book a call

About our clinically validated cancer biomarkers

Circulating Tumour DNA (ctDNA)

The extraction of ctDNA from a simple blood sample is recognised by international clinical guidelines, including ESMO’s recommendations for advanced cancer, as a valid method to identify actionable mutations and direct targeted therapies without the need for invasive surgery.

Tumour Mutational Burden (TMB)

Tumour Mutation Burden (TMB) measures the total number of mutations present in your cancer cells. Massive pan-tumour studies have shown that a high mutational burden is extensively linked to improved responses to modern immunotherapies across a wide range of solid tumours.

Microsatellite Instability (MSI)

Microsatellite Instability (MSI) is a critical feature of how DNA repairs itself. Peer-reviewed research establishes MSI as a predictive biomarker for cancer immunotherapy, helping oncologists understand if your immune system can be effectively stimulated to attack the tumour.

Tumour Fraction (TFx) Estimates

Your report includes a Tumour Fraction estimate, which calculates the proportion of the cell-free DNA isolated in your blood sample that is tumour DNA. Accurately measuring this is emerging as a powerful non-invasive biomarker to assess overall tumour burden and monitor disease progression.

Who these tests are designed for

People with a confirmed cancer diagnosis
People seeking tumour genomic testing (not inherited genetics)
Those wanting clearer insight into tumour biology and possible next steps

What they are not

Not for cancer screening
Not for hereditary / family risk testing
Not a substitute for medical care

To explore our cancer genetic testing further, please book a free discovery call using the calendar below.

Want to learn more about ctDNA testing?

Demystifying cancer genomics: In this short video series, Medical Oncologist Dr. Christoph Oing explains how analysing ctDNA from a simple blood sample may reveal personalised, targeted treatment options for your cancer.

About our tests

Our liquid biopsy tests work by analysing cell-free DNA (cfDNA) circulating in your blood to identify and characterise tumour-derived fragments (circulating tumour DNA, or ctDNA).
Our tissue-based tests work by analysing tumour DNA from samples stored by your hospital following biopsy or surgery.
The tests use Next Generation Sequencing (NGS) on high throughput Illumina platforms to provide a genomic profile of your cancer.
Our tests are extensively validated, accredited by the American College of Pathologists (CAP) and performed in an ISO 15198 accredited laboratory.
Analysis and reporting is undertaken as per international guidelines (ACMG/AMP/ASCO/CAP) using a CE-IVD certified mutation database for variant interpretation and reporting.
The output from the cancer genetic testing is a report highlighting genetic variants found, providing information for clinicians on the potential relevance of any variants, and a list of UK clinical trials that might be treatment options based on the genomic profile of your cancer.

Regulatory information / disclaimer

RareCan Insight genomic tests are registered with the Medicines and Healthcare products Regulatory Agency (MHRA) as Class 1 in vitro diagnostic medical devices.
They are intended for use by healthcare professionals for the qualitative identification of specific somatic variants in circulating tumour DNA (ctDNA) extracted from human whole blood or tumour DNA (tDNA) extracted from tumour tissue samples.
The tests are intended to support clinicians in identifying potential clinical trials for which you may be eligible.
The sample collection kits are intended for use by qualified phlebotomists and are not intended for patient self-testing or self-sampling.
Results must be interpreted by a qualified healthcare professional in conjunction with your full clinical history, other diagnostic test results, and relevant clinical guidelines.
The results are not intended to be used as the sole basis for treatment decisions, and further confirmatory testing may be required.